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Abstract
Primary central nervous system lymphoma (PCNSL) risk is greatly increased in 
immunosuppressed HIV-infected people. Using data from the United States transplant registry 
linked with 17 cancer registries (1987–2014), we studied PCNSL and systemic non-Hodgkin 
lymphoma (NHL) in 288,029 solid organ transplant recipients. Transplant recipients had elevated 
incidence for PCNSL compared with the general population (standardized incidence ratio=65.1; 
N=168), and this elevation was stronger than for systemic NHL (standardized incidence 
ratio=11.5; N=2,043). Compared to kidney recipients, PCNSL incidence was lower in liver 
recipients (adjusted incidence rate ratio [aIRR]=0.52), similar in heart and/or lung recipients, and 
higher in other/multiple organ recipients (aIRR=2.45). PCNSL incidence was higher in Asians/
Pacific Islanders than non-Hispanic whites (aIRR=2.09); after induction immunosuppression with 
alemtuzumab (aIRR=3.12), monoclonal antibodies (aIRR=1.83), or polyclonal antibodies 
(aIRR=2.03); in recipients who were Epstein-Barr virus-seronegative at the time of transplant and 
at risk of primary infection (aIRR=1.95); and within the first 1.5 years after transplant 
(aIRR>2.00). Compared to other recipients, those with PCNSL had increased risk of death 
(adjusted hazard ratio [aHR]=11.79) or graft failure/retransplantation (aHR=3.24). Recipients with 
PCNSL also had higher mortality than those with systemic NHL (aHR=1.48). In conclusion, 
PCNSL risk is highly elevated among transplant recipients, and it carries a poor prognosis.
INTRODUCTION
Approximately 30,000 solid organ transplants are performed every year in the United States 
(1). Prolonged immunosuppressive therapy administered to transplant recipients to prevent 
graft rejection carries an increased risk of cancer in the post-transplant period (2). Non-
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Hodgkin lymphomas (NHLs) are one of the frequent malignancies in transplant recipients 
and comprise part of the spectrum of post-transplant lymphoproliferative disorder (PTLD) 
(3).
Extranodal involvement in NHLs among transplant recipients is common, but primary 
involvement of the central nervous system (CNS) is rare (3–6). Primary CNS lymphomas 
(PCNSLs) affect the brain, leptomeninges, or spinal cord without evidence of any systemic 
involvement (4, 6). Among individuals infected with human immunodeficiency virus (HIV), 
PCNSL is a condition that marks the onset of acquired immunodeficiency syndrome 
(AIDS), and its risk is greatly increased in HIV-infected individuals (7). Few cases of 
PCNSL have also been reported in patients with primary immunodeficiency disorders, such 
as Wiskott-Aldrich syndrome and severe combined immunonodeficiency disorder (8). 
However, data on PCNSL risk in other immunosuppressed individuals, such as transplant 
recipients, are lacking.
PCNSLs are usually aggressive diffuse large B-cell lymphomas (DLBCLs), and tumor cells 
are positive for Epstein-Barr virus (EBV) in more than 90% of the cases (9, 10), which 
differs from PCNSLs in immunocompetent individuals where EBV-related PCNSL cases are 
uncommon (11). The CNS is an immunologically privileged site, and prolonged suppression 
of T-cell mediated immunity may allow an EBV-driven oncogenic process (5, 6, 12). 
PCNSLs often carry a poor prognosis and are associated with high mortality (4, 10, 13–15). 
Treatment for PCNSL in transplant recipients usually includes reducing the dose of 
immunosuppressive drugs, which may increase the risk of graft failure (9). Studies on 
prognosis, however, have been limited by small sample sizes, inclusion of other extranodal 
NHLs, and absence of evaluation of graft failure as an outcome (16–19).
Since PCNSL is a rare malignancy, studies in transplant recipients have mostly been 
descriptive case series (9, 10, 13, 17–22). The Transplant Cancer Match (TCM) Study 
provides a unique opportunity to study rare cancers that develop in transplant recipients (2). 
In this study, we utilized TCM data to describe PCNSL incidence in transplant recipients 
compared to the general population, evaluate various risk factors for its occurrence, and 
report on outcomes following PCNSL diagnosis. We also compare PCNSL with NHLs at 
other sites to provide insights regarding etiology and prognosis.
MATERIALS AND METHODS
The TCM Study links the US Scientific Registry of Transplant Recipients (SRTR) with 
population-based cancer registries (2). The SRTR provides information on all US solid organ 
transplant recipients beginning in 1987, including demographics, medical characteristics, 
transplanted organs, and induction and baseline maintenance immunosuppressive 
medications. Record linkages were completed between the SRTR and 17 cancer registries 
covering approximately 51% of the US transplant population (see Table 1 note). We 
included transplant recipients residing in the geographic areas covered by the participating 
cancer registries, and excluded those who had unknown race/ethnicity (N=1,878), a cancer 
registry diagnosis of NHL before transplantation (N=609), or SRTR diagnosis of HIV 
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infection (N=530). This study was approved by human subjects review committees at the 
National Cancer Institute and, as required, participating cancer registries.
Incident NHLs were identified from the linked cancer registries using the International 
Classification of Diseases for Oncology, 3rd edition codes (ICD-O-3) (23). Since most 
PCNSLs are DLBCL, we assessed only NHLs that were recorded as DLBCL or unspecified 
NHL (most of which would have been DLBCLs) using ICD-O-3 morphology codes 
(DLBCL: 9678–9680, 9684, 9688, 9735, 9737; unspecified NHL: 9590–9596, 9675, 9820, 
9970). PCNSL cases were then defined using topography codes for the CNS (C70.0–C72.9), 
while systemic NHLs were the remaining NHLs at other sites.
Statistical analyses
The follow-up began at transplantation or the start of cancer registry coverage (whichever 
came later), and ended at the earliest of death, graft failure or retransplantation, loss to 
follow-up, or the last date of cancer registry coverage. We compared incidence of PCNSL 
and systemic NHL in transplant recipients to the general population using standardized 
incidence ratios (SIRs), obtained by dividing the observed number of cases by the expected 
number in the general population. Since the AIDS epidemic has strongly affected 
contemporaneous general population rates for PCNSL since 1980 (24), we calculated the 
expected number of cases by applying general population cancer incidence rates for DLBCL 
and unspecified NHL obtained from the Surveillance, Epidemiology, and End Results 
(SEER) program for 1973–1979 to person-time at risk among transplant recipients, stratified 
by sex and age (5-year groups). The comparison to pre-1980 expected counts allows the SIR 
to better capture the impact of transplantation on increasing risk above that seen in a largely 
immunocompetent population. We present exact confidence intervals for the SIRs.
We used Poisson regression to compare PCNSL and systemic NHL incidence among 
subgroups of transplant recipients, defined by demographic characteristics, transplanted 
organ, induction and baseline immunosuppressive medications, EBV serostatus at the time 
of transplantation, and time since transplantation. Factors significantly associated with 
PCNSL incidence in univariate Poisson models, or otherwise believed to be clinically 
important, were included in multivariable models for PCNSL and systemic NHL. Although 
EBV serostatus was not significantly associated with PCNSL in univariate analyses (Table 
S1), it is an important risk factor for NHL in transplant recipients. Therefore, we included 
this variable in multivariable analyses. To determine whether risk factors differed for the two 
NHL types, we compared PCNSL and systemic NHL in a multivariable logistic regression 
model that included the predictors from the Poisson model.
We evaluated the impact of PCNSL or systemic NHL on transplant outcomes in two 
additional analyses. First, we evaluated whether PCNSL or systemic NHL in transplant 
recipients is associated with risk of death, graft failure/retransplantation, or the composite 
outcome using Cox regression. The time scale was time since transplantation, and diagnosis 
of PCNSL or systemic NHL was included as a time-dependent variable. Adjusted hazard 
ratios (aHRs) are presented incorporating adjustment for age at transplantation, sex, 
transplanted organ, year of transplantation, and race/ethnicity. As some transplants could 
have occurred before the start of cancer registry coverage, we allowed for delayed entry. 
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Second, we compared risk of death among transplant recipients with PCNSL and those with 
systemic NHL using Cox regression with time since NHL diagnosis as the time scale. This 
analysis included only the NHL cases. Follow-up continued through any graft failure or 
retransplantation events and ended at death, loss to follow-up, or the last date of the cancer 
registry coverage (whichever occurred earlier). We conducted an additional survival analysis 
adjusted for cancer treatment. The proportional hazards assumption was tested by 
introducing interaction terms of PCNSL or systemic NHL diagnosis with follow-up time and 
was met for all models. We plot Kaplan-Meier survival curves to characterize the probability 
of death following PCNSL or systemic NHL diagnosis. Some cancer registries did not 
provide complete information on survival or cancer treatment and were excluded from the 
relevant survival analyses (see Table 3 and Supplementary Table 2 notes).
We also ascertained EBV status of the NHL tumors. Cancer registries do not collect this 
information, but it is collected by the SRTR for PTLD cases. We therefore searched for 
SRTR records on PTLD and, if available, used the EBV data closest in time to the 
corresponding matched NHL diagnosis in the cancer registry.
RESULTS
Among the 288,029 transplants included in the study, the kidney was the most frequently 
transplanted organ (58.0%), followed by liver (21.7%), heart and/or lung (14.4%), and other/
multiple organs (5.9%) (Table 1). A large proportion of transplants occurred between the 
ages 50–64 years (37.7%), in males (61.4%), and in non-Hispanic whites (62.4%). The 
median follow-up time for all included transplants was 4.0 years (interquartile range, 1.5–7.7 
years).
During follow-up, 168 cases of PCNSL and 2,043 cases of systemic NHL were diagnosed 
(incidence 11.5 and 140.0 per 100,000 person-years, respectively). PCNSL and systemic 
NHL occurred at a median of 1.7 years and 3.3 years after transplant, respectively. 
Compared to the general population, incidence was substantially elevated for both PCNSL 
(SIR=65.1; 95%CI=55.6–75.7) and systemic NHL (SIR=11.5; 95%CI=11.0–12.0).
As shown in Table 2, PCNSL incidence appeared to increase with age but the differences 
were not significant. PCNSL incidence did not differ by sex, while Asians/Pacific Islanders 
had 2-fold higher incidence (aIRR=2.09; 95%CI=1.24–3.52) than non-Hispanic whites. 
Compared with kidney recipients, risk was lower for liver recipients (aIRR=0.52; 
95%CI=0.31–0.92), not different for heart and/or lung recipients, and higher for other/
multiple organ recipients (aIRR=2.45; 95%CI=1.54–3.90). Regarding drugs used for 
induction immunosuppression, PCNSL incidence was higher with administration of 
alemtuzumab (aIRR=3.12; 95%CI=1.57–6.22), monoclonal antibodies (aIRR=1.83; 
95%CI=1.03–3.28), or polyclonal antibodies (aIRR=2.03; 95%CI=1.35–3.06), compared to 
no induction drugs. Transplant recipients who were EBV-seronegative at the time of 
transplant had higher PCNSL incidence (aIRR=1.95; 95%CI=1.09–3.48) than EBV-
seropositive recipients. PCNSL incidence was greatest within the first 1.5 years after 
transplant (Figure 1), then gradually decreased over time. No significant differences in 
incidence were observed with respect to body mass index, donor type (for kidney recipients), 
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baseline maintenance immunosuppressive drugs, cytomegalovirus serostatus, or human 
leukocyte antigen (HLA) mismatches (Table S1).
The pattern for systemic NHLs differed from that for PCNSL for some, but not all variables 
(Table 2). Systemic NHL incidence was high in young transplant recipients (age at 
transplantation, 0–17 years), decreased with increasing age until 35–49 years, and then 
increased again, with highest incidence in people ≥65 years at transplantation (Table 2). 
Incidence of systemic NHLs was lower among females compared to males, and among non-
Hispanic blacks and Hispanics compared to non-Hispanic whites. In contrast with PCNSL, 
high incidence of systemic NHLs was observed among liver (aIRR=1.35; 95%CI=1.19–
1.52), heart and/or lung (aIRR=2.05; 95%CI=1.83–2.29), and other/multiple organ recipients 
(aIRR=1.88; 95%CI=1.56–2.25), compared to kidney recipients. Incidence declined with 
calendar year of transplant (aIRR=1.53 for 1987–1994 and aIRR=0.74 for 2010–2014, vs. 
2000–2004). Risk of systemic NHLs was elevated with induction immunosuppression using 
alemtuzumab (aIRR=1.56; 95%CI=1.18–2.07) or monoclonal antibody (aIRR=1.28; 
95%CI=1.08–1.53) but not with polyclonal antibody or IL-2 receptor antagonists, compared 
to no induction drugs. Similar to PCNSL, higher incidence of systemic NHLs was observed 
in EBV-seronegative recipients (aIRR=3.01; 95%CI=2.57–3.52). The pattern with respect to 
time since transplant was similar between PCNSL and systemic NHL (Figure 1), although 
the magnitude of the peak in the early post-transplant period was lower in systemic NHL. 
The patterns for PCNSL and systemic NHL differed for age at transplantation (p=0.010), 
race/ethnicity (p=0.024), transplanted organs (p<0.001), year of transplantation (p=0.024), 
induction immunosuppression (p=0.017), and time since transplantation (p=0.001) (Table 2).
EBV status of the tumors could be ascertained for 48 (28.6%) PCNSLs and 771 (37.7%) 
systemic NHLs. Of these, 43 (90%) PCNSL cases were EBV positive compared to 462 
(60%) systemic NHL cases (p<0.0001).
PCNSL was associated with increased risk of death (aHR=11.79; 95%CI=9.37–14.83), graft 
failure/retransplantation (aHR=3.24; 95%CI=2.19–4.78), and the combined endpoint of 
death/graft failure/retransplantation (aHR=7.01; 95%CI=5.75–8.55), compared to transplant 
recipients without any NHL. An elevated risk of these outcomes was also observed after 
diagnosis of systemic NHLs, but the increase was smaller (Table 3). In an analysis that 
ignored graft failure and continued to follow NHL patients across multiple transplants, 
recipients with PCNSL had increased risk of death compared to those with systemic NHLs 
(aHR=1.48; 95%CI=1.14–1.92) (Figure 2). We further evaluated the receipt of treatment 
after NHL diagnosis and its effect on survival in an analysis restricted to registries that 
provided treatment information (Table S2). Of the 117 PCNSL cases, 19 (16.2%) received 
neither chemotherapy nor radiation, 17 (14.5%) received only radiation, 31 (26.5%) received 
only chemotherapy, 24 (20.5%) received both, and treatment information on 26 (22.2%) 
cases was unknown. After additional adjustment for cancer treatment, PCNSL remained 
associated with increased risk of death compared to systemic NHLs (aHR=1.41; 
95%CI=1.08–1.85). The median survival times after PCNSL and systemic NHL diagnosis 
were 1.1 and 2.7 years, respectively, while the 5-year overall survival rates for PCNSL and 
systemic NHL were 35% (95%CI=24–47%) and 43% (95%CI=40–46%), respectively.
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DISCUSSION
Solid organ transplant recipients have an increased risk of cancers, including NHLs, largely 
due to iatrogenic immunosuppression (2). In a comprehensive analysis of a large cohort of 
solid organ transplant recipients, we demonstrate that PCNSL incidence is substantially 
elevated in transplant recipients compared to the general population. We identified that 
incidence is higher among transplant recipients who receive certain induction 
immunosuppression regimens and those who are EBV-seronegative at the time of transplant. 
In addition, a large fraction of PCNSL tumors were EBV-positive. These results highlight 
the likely etiologic roles of iatrogenic immunosuppression and EBV infection in the post-
transplant period in contributing to the development of PCNSL. We also demonstrated that 
both systemic NHL and PCNSL adversely affect survival in transplant recipients, but 
PCNSL carries a worse prognosis.
PCNSL is a rare malignancy and its risk is highly elevated in immunosuppressed individuals 
such as HIV-infected people (7). Several case series have described primary CNS 
involvement in PTLDs diagnosed after solid organ transplantation (9, 10, 20, 21, 25–27). 
However, very few reports in transplant recipients focused on PCNSLs, which are extranodal 
NHLs and thus comprise a subset of monomorphic PTLDs (17, 18). PCNSL is a distinct 
clinicopathological disease compared to systemic non-CNS NHLs and the 2008 World 
Health Classification of lymphoid neoplasms defined “Primary CNS DLBCL” as a new 
entity (28).
In particular, PCNSLs differ in their gene expression and genomic profile compared to 
systemic NHL (29–33). PCNSL tumor cells are characterized by downregulation or loss of 
expression of HLA class I and II genes which may help them escape immune surveillance 
(29, 32, 33). Along with the vascular endothelial cells in the CNS, these tumor cells also 
express high levels of interleukin-4 and STAT6 which support B-cell growth (30). A 
genome-wide gene expression comparison between PCNSL and non-CNS DLBCL 
identified several signatures unique to PCNSL, including expression of genes related to 
extracellular matrix and cellular adhesion pathways leading to CNS tropism, B-cell 
migration, lymphoproliferation, and aggressive clinical features (31). In this study, we found 
some differences in between transplant recipients who developed PCNSL and those with 
systemic NHL in terms of demographic characteristics, transplanted organs, induction 
immunosuppression, and time since transplantation, further suggesting that PCNSL and 
systemic NHL are etiologically distinct entities.
For instance, we did not observe an association between age at transplantation and PCNSL 
incidence independent of recipients’ EBV serostatus, which may be due to the small number 
of PCNSL cases. Nonetheless, a distinct pattern was observed for systemic NHL, where the 
incidence was high in the youngest (0–17 years) and the oldest (65+ years) age groups. 
Associations between age and NHL risk in transplant recipients have been described 
previously (16, 34), and might be related to control of primary EBV infection in children or 
processes related to aging in older adults. EBV-seronegative transplant recipients have a high 
risk of acquiring the infection in the post-transplant period (35, 36). Prolonged 
immunosuppression and lack of EBV-specific T-cell immune responses may lead to 
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unchecked monoclonal expansion of EBV-infected B-cells and development of lymphoma 
(37). The elevated incidence of PCNSL among EBV-seronegative recipients in this study, 
and the increase in incidence within 1.5 years following transplant, support the role of 
primary EBV infection in contributing to PCNSL. Similar findings have been reported 
previously for NHLs overall and DLBCL in transplant recipients (22, 34, 38–40), although 
in our study, the pattern for PCNSL incidence according to time since transplantation was 
stronger than for systemic NHLs.
To some extent, the pattern in PCNSL incidence also reflects the degree of 
immunosuppression among transplant recipients. The relatively high incidence associated 
with “other/multiple” organ transplants and low incidence for liver transplants may be due to 
differences in the intensity of immunosuppressive regimens. Perhaps surprisingly, however, 
recipients of a heart and/or lung did not have higher PCNSL incidence than kidney 
recipients, even though they typically receive intensive immunosuppression. Induction 
immunosuppressive drugs given immediately post-transplant to prevent acute rejection 
include anti-CD3 monoclonal antibodies (OKT3), alemtuzumab, IL-2 receptor antagonists, 
and polyclonal antibodies such as anti-thymocyte globulin (41, 42). We previously reported 
that alemtuzumab induction was associated with an increased risk of NHL, colorectal 
cancer, and thyroid cancer among kidney recipients (43). Herein, we demonstrated that 
PCNSL risk was increased after induction with alemtuzumab, monoclonal antibodies, and 
polyclonal antibodies. The incidence of systemic NHL was also increased after 
alemtuzumab and monoclonal antibodies, but not polyclonal antibodies, although it is 
unclear why this pattern differs between PCNSL and systemic NHL.
We also showed that Asians/Pacific Islanders had more than twice the incidence of PCNSL 
compared with non-Hispanic whites, while the incidence of systemic NHL was highest 
among non-Hispanic whites. The reason for this difference is unknown. A previous analysis 
of SEER data found that PCNSL incidence was similar for non-Hispanic whites and Asians/
Pacific Islanders in adults over 50 years of age in the US general population (a largely 
immunocompetent population among whom the prevalence of HIV-infected individuals and 
transplant recipients is low) (44). Similar analyses for younger individuals in the US 
population (0–49 years) found a higher PCNSL risk in non-Hispanic blacks, which may be 
attributed to the higher prevalence of HIV infection in this group (44, 45).
We found that PCNSL increased the risk of death and graft failure/retransplantation in 
transplant recipients compared to recipients without any NHL. The risk was also increased 
after systemic NHL, but the magnitude was much lower. Furthermore, when we restricted 
the analysis to NHL cases, transplant recipients with PCNSL had a 1.5-fold increased risk of 
dying compared to recipients with systemic NHL. PCNSL has a low 5-year survival rate of 
30% even in immunocompetent individuals (15). The 5-year survival rate after PCNSL was 
similar among transplant recipients in our study as has been reported for immunocompetent 
individuals, but lower than for recipients with systemic NHL. PCNSL treatment is centered 
around the use of high dose methotrexate-based chemotherapy, and whole-brain 
radiotherapy (considered to be a standard-or-care till the early 1990s) is often used as a 
salvage therapy (46). Rituximab, an anti-CD20 monoclonal antibody that has been the 
mainstay of treatment of systemic NHLs, has poor CNS penetration (47, 48). Furthermore, 
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patients with renal insufficiency, older age, or poor performance status - factors that are 
often present in transplant recipients - may not be candidates for high-dose methotrexate 
therapy and may receive palliative whole-brain radiotherapy or supportive care (46). 
Mortality in PCNSL patients may be caused by involvement of CNS itself, particularly the 
deep structures within the brain (49), or delayed neurotoxic effects of therapy (50). 
Management of PCNSL in transplant recipients has an added complexity as it occurs on the 
background of iatrogenic immunosuppression. Often, the dose of immunosuppressive drugs 
may be reduced or drugs may be changed as part of the treatment for PCNSL (9), which can 
increase the risk of graft failure. We observed a three-fold elevated risk of graft failure/
retransplantation following PCNSL, which contributes to the high mortality.
A strength of our study was the use of a population-based cohort that was representative of 
US transplant recipients, and the linkage to cancer registries allowed for largely complete 
and unbiased ascertainment of NHL diagnoses. The large sample size allowed us to evaluate 
the PCNSL incidence for different patient subgroups. We were also able to compare 
incidence and outcomes for PCNSL and systemic NHLs. However, our study had some 
limitations. Due to the rarity of PCNSL, the number of cases was modest, which affected the 
precision of estimates for some subgroups. EBV serostatus was not available for many 
transplant recipients, and EBV status of the tumors could not be directly ascertained and was 
frequently missing, which precluded us from evaluating the role of this virus in detail. We 
evaluated the risk of NHLs and hence focused on monomorphic PTLD cases; a fraction of 
PTLD cases affecting the CNS are described as polymorphic PTLD (10), which we did not 
capture. Also, information on only the initial maintenance immunosuppressive therapy was 
available, so we could not evaluate the effect of changes in the medication regimen over 
time.
In conclusion, PCNSL risk is highly elevated in solid organ transplant recipients, 
particularly within the first 1.5 years after transplant. Although it is a rare malignancy, 
physicians managing the care of transplant recipients should be aware about this heightened 
risk, particularly for recipients who are EBV-seronegative at the time of transplant, and those 
who are treated with alemtuzumab, monoclonal antibodies, or polyclonal antibodies for 
induction immunosuppression. As some risk factors for PCNSL differ from that of systemic 
NHL, the possibility of etiologic heterogeneity should be explored in other populations. The 
prognosis of PCNSL in transplant recipients is poor, pointing to a need to develop improved 
therapies for this malignancy.
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Figure 1. Risk of primary CNS lymphoma and systemic non-Hodgkin lymphomas in solid organ 
transplant recipients, according to time since transplantation
The figure plots the adjusted incidence rate ratios (y-axis) for primary CNS lymphoma and 
systemic non-Hodgkin lymphomas in solid organ transplant recipients according to time 
since transplantation in years (x-axis). The comparison time period is 0.01 to 0.50 years after 
transplant, and the rate ratios were estimated at 0.51–1.00, 1.01–1.49, 1.50–2.00, 2.01–3.00, 
3.01–5.00, 5.01–10.00, and >10.00 years after transplant. The adjusted incidence rate ratios 
are from the multivariable model in Table 1 and are plotted at the midpoint of each time 
interval. CNS, central nervous system; IRR, incidence rate ratio; NHL, non-Hodgkin 
lymphoma.
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Figure 2. Survival after diagnosis of primary CNS lymphoma or systemic non-Hodgkin 
lymphomas in solid organ transplant recipients
The figure shows Kaplan-Meier curves that represent the probability of survival after 
diagnosis of primary CNS lymphoma or systemic non-Hodgkin lymphomas in solid organ 
transplant recipients. The probability of survival is plotted on the y-axis, while the follow-up 
time after a diagnosis of the non-Hodgkin lymphomas is depicted on the x-axis. The hazard 
ratio is adjusted for age at transplantation, sex, race/ethnicity, year of transplantation, and 
organ transplanted. CI, confidence intervals; CNS, central nervous system; HR, hazard ratio; 
NHL, non-Hodgkin lymphoma
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Table 1
Characteristics of US solid organ transplants included in the study population
Characteristics Number of transplants
(%)
Total 288,029 (100)
Age at transplantation, years
  0–17 21,121 (7.3)
  18–34 44,001 (15.3)
  35–49 86,250 (29.9)
  50–64 108,506 (37.7)
  65+ 28,151 (9.8)
Sex
  Male 176,853 (61.4)
  Female 111,176 (38.6)
Race/ethnicity
  Non-Hispanic white 179,699 (62.4)
  Non-Hispanic black 50,073 (17.4)
  Hispanic 42,684 (14.8)
  Asians/Pacific Islander 15,573 (5.4)
Organ transplanted
  Kidney 167,207 (58.0)
  Liver 62,405 (21.7)
  Heart and/or Lung 41,496 (14.4)
  Other/Multiple 16,921 (5.9)
Year of transplantation
  1987–1994 44,128 (15.3)
  1995–1999 59,657 (20.7)
  2000–2004 73,225 (25.4)
  2005–2009 82,152 (28.5)
  2010–2014 28,867 (10.0)
Participating registries with years of coverage: California (1988–2012), Colorado (1988–2009), Connecticut (1973–2009), Florida (1981–2009), 
Georgia (1995–2010), Hawaii (1973–2007), Illinois (1986–2013), Iowa (1973–2009), Kentucky (1995–2011), Michigan (1985–2009), New Jersey 
(1979–2010), New York (1976–2010), North Carolina (1990–2010), Pennsylvania (1985–2013), Seattle-Puget sound area of Washington (1974–
2014), Texas (1995–2010), and Utah (1973–2008).
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